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Cis-Regulatory Variants Affect CHRNA5 mRNA Expression
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Abstract
Variants within the gene cluster encoding a3, a5, and b4 nicotinic receptor subunits are major risk factors for substance
dependence. The strongest impact on risk is associated with variation in the CHRNA5 gene, where at least two mechanisms
are at work: amino acid variation and altered mRNA expression levels. The risk allele of the non-synonymous variant
(rs16969968; D398N) primarily occurs on the haplotype containing the low mRNA expression allele. In populations of
European ancestry, there are approximately 50 highly correlated variants in the CHRNA5-CHRNA3-CHRNB4 gene cluster and
the adjacent PSMA4 gene region that are associated with CHRNA5 mRNA levels. It is not clear which of these variants
contribute to the changes in CHRNA5 transcript level. Because populations of African ancestry have reduced linkage
disequilibrium among variants spanning this gene cluster, eQTL mapping in subjects of African ancestry could potentially
aid in defining the functional variants that affect CHRNA5 mRNA levels. We performed quantitative allele specific gene
expression using frontal cortices derived from 49 subjects of African ancestry and 111 subjects of European ancestry. This
method measures allele-specific transcript levels in the same individual, which eliminates other biological variation that
occurs when comparing expression levels between different samples. This analysis confirmed that substance dependence
associated variants have a direct cis-regulatory effect on CHRNA5 transcript levels in human frontal cortices of African and
European ancestry and identified 10 highly correlated variants, located in a 9 kb region, that are potential functional
variants modifying CHRNA5 mRNA expression levels.
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[11,18]. The strongest impact on the risk of substance abuse and
lung cancer is associated with variation in CHRNA5.
Our previous studies showed there are at least two possible
biological mechanisms accounting for these associations: an amino
acid variation in exon 5 of CHRNA5 (rs16969968; D398N), which
likely alters protein structure and receptor function and variation
in CHRNA5 mRNA expression levels [8,19,20]. In European
American populations, the nicotine dependence risk allele (minor
allele) of the non-synonymous variant (rs16969968; D398N)
primarily occurs on the haplotype containing the low mRNA
expression allele of CHRNA5. The major allele at rs16969968
occurs on both high and low expression haplotypes. When the

Introduction
Several genome-wide association studies have linked chromosome 15q24-q25.1, a region containing the genes encoding the a3,
a5, and b4 subunits of neuronal nicotinic receptors, with nicotine
dependence and smoking-related illnesses such as lung cancer,
airflow obstruction, and chronic obstructive pulmonary disease [1–
6]. In candidate gene association studies, variants in the CHRNA5A3-B4 gene cluster have been associated with nicotine dependence
[7–14], smoking behaviors [15,16], level of response to alcohol
[17], age of initiation of drinking [15] and cocaine dependence
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from the National Institute of Child Health and Human
Development (NICHD) brain and tissue bank for developmental
disorders at the University of Maryland (http://medschool.
umaryland.edu/btbank/); (b) tissue derived from 66 unrelated
European Australians (35 alcoholics and 31 controls) was received
from the Australian Brain Donor Programs NSW Tissue Resource
Centre (http://sydney.edu.au/medicine/pathology/trc); (c) tissue
derived from 45 unrelated, non-demented elderly European
Americans was obtained from the Knight Alzheimer’s Disease
Research Center at Washington University (http://alzheimer.
wustl.edu/); (d) cDNA and gDNA from 120 lymphoblastoid cell
lines were obtained from the Rutgers University Cell and DNA
Repository (http://www.rucdr.org/). These lymphoblastoid cell
lines were generated from 60 unrelated African Americans and 60
unrelated European Americans, who were selected from the
COGA dataset based on the genotypes of rs3841324 from our
previous study [20]. In the African American subset, 24 subjects
are homozygous for the major allele of rs3841324, 21 subjects are
homozygous for the minor allele, and 15 subjects are heterozygous. In the European American subset, 21 subjects are
homozygous for the major allele of rs3841324, 18 subjects are
heterozygous, and 21 subjects are homozygous for the minor
allele. The Washington University IRB reviewed the protocol
using brain tissue and determined it was exempt from approval.
The study using the COGA dataset was approved by IRB at all
participating institutions. All data were analyzed anonymously.

major allele occurs on the low mRNA expression haplotype of
CHRNA5, the risk for nicotine dependence and lung cancer is
significantly lower when compared to major alleles on the higher
mRNA expression haplotype [19]. Lung cancer studies also
demonstrated up-regulation of CHRNA5 mRNA expression in
lung adenocarcinomas, compared to normal lung tissue [21,22]. In
addition, CHRNA5 mRNA expression in normal lung tissue was
significantly associated with the genotype of rs16969968. mRNA
expression level was about 2.5-fold lower in patients who are
homozygous for the minor allele of rs16969968 than patients who
are homozygous for the major allele [22].
There are approximately 50 variants spanning ,83 kb within
and flanking the CHRNA5-A3-B4 gene cluster and the adjacent
PSMA4 gene that are highly correlated (D9$0.9; r2$0.7) with the
variants (i.e. rs3841324, rs588765, rs880395) associated with
CHRNA5 mRNA levels in populations of European ancestry
(Table S1). It is not clear which of these variants directly affect
CHRNA5 mRNA expression. Because populations of African
ancestry have reduced linkage disequilibrium (LD) patterns across
this gene cluster (http://hapmap.ncbi.nlm.nih.gov) (Table S1), the
contrasting genetic architecture in Africans and Europeans can be
leveraged to identify the functional variation most tightly linked to
differences in CHRNA5 mRNA expression. A previous study using
quantitative allele specific gene expression in prefrontal cortex
tissue from 59 Caucasians and 14 African Americans reported a
cluster of 6 highly correlated SNPs located ,13.5 kb upstream of
the CHRNA5 gene that accounted for the variability in mRNA
expression [23]. Differential allelic expression of CHRNA5 was also
detected in normal lung tissue and in lung adenocarcinoma; two
single nucleotide polymorphisms (rs55853698 and rs55781567) in
the 59UTR of CHRNA5 were associated with significant imbalance
in allelic expression ratio [24]. However, another study with 6
samples derived from human frontal cortex, amygdala or nucleus
accumbens showed only one of the 6 samples revealed significant
CHRNA5 allelic expression imbalance in amygdala and nucleus
accumbens, but not in frontal cortex [25]. The subject which
showed allelic expression imbalance was heterozygous for 2 SNPs
in ,13.5 kb region upstream of the gene, but was homozygous for
the variant (rs3841324) in the promoter region adjacent to
CHRNA5 transcription start site [25].
Our previous studies in frontal cortices of European ancestry
demonstrated significant cis-regulatory effects on the CHRNA5
mRNA levels. In contrast only modest variation in CHRNA3 or
CHRNB4 mRNA levels were detected in our sample and these
were not associated with SNP variation. In this study, we focused
on CHRNA5. We first examined the CHRNA5 mRNA variability in
frontal cortices derived from 49 African Americans and confirmed
our previous observation in other ethnic population. Further, we
quantified CHRNA5 allelic mRNA expression in frontal cortices
derived from 66 European Australians, 45 European Americans,
and 49 African Americans, to investigate the putative cisregulatory variants that affect mRNA expression of this gene.
Because several cis-regulatory variants for CHRNA5 mRNA
expression are located in the PSMA4 gene region, we also
examined the influence of these variants on PSMA4 mRNA
expression to clarify whether the cis-regulatory effect is specific for
CHRNA5 mRNA expression.

Genotyping
We used the Qiagen DNeasy Blood and Tissue Kit (Qiagen,
Valencia, California, USA) to extract DNA from brain tissue. We
used the PrimerPicker software (http://www.kbioscience.co.uk/
primer-picker/) to design the assay and followed the protocol
described in the KASPar SNP Genotyping System manual
(http://www.kbioscience.co.uk) to run PCR reactions with an
ABI GeneAmp PCR System 9700 (Applied Biosystems www.
AppliedBiosystems.com). Genotypes were evaluated using an ABI
instrument, 7900 HT Fast Real-Time PCR system. The 22-bp
insertion/deletion variant, rs3841324 was genotyped using
electrophoresis method described in our previous study [20]. We
used Haploview software (v3.2) [26], to infer the LD structure of
the genome in the region containing loci associated with CHRNA5
expression in brain samples tested.

Quantitative real-time total mRNA expression assay
We used the Qiagen RNeasy and Lipid Tissue kit (Qiagen,
Valencia, CA, USA) to extract total RNA from brain tissue. RNA
concentration was measured with a NanoDrop 2000 spectrophotometer (Thermo Scientific, Pittsburgh, Philadelphia, USA) and 5–
10 ug total RNA was converted to cDNA with a High Capacity
cDNA Archive kit (http://www.appliedbiosystems.com). TaqMan
assays were used to quantify the total mRNA expression of
CHRNA5 (Hs00181248_m1; Applied Biosystems, CA, USA), and
PSMA4 (Hs01002583_m1) in human frontal cortices. Gene
expression levels were assessed by real-time PCR using an ABI7900HT Fast real-time PCR system. Each real-time PCR run
included within-plate triplicates. Correction for sample-to-sample
variation was done by simultaneously amplifying GAPDH
(Hs02758991_g1) as a reference. We used the comparative Ct
method to analyze total mRNA expression levels of CHRNA5 and
PSMA4 and then normalized with GAPDH mRNA expression to
obtain relative total mRNA expression level. A detailed protocol is
described in Wang et al. [19,20].

Materials and Methods
Study subjects
Three sets of postmortem brain tissues from the frontal cortex
and one set of lymphoblastoid cells were tested in this study: (a)
tissue derived from 49 unrelated African Americans was obtained
PLOS ONE | www.plosone.org

2

November 2013 | Volume 8 | Issue 11 | e80204

Cis-Regulatory Effect on CHRNA5 mRNA Expression

ranges from 94% to 100%. Real-time data were analyzed using
the comparative Ct method [28] and were corrected for the PCR
efficiency of each assay. In each cDNA sample, the delta Ct (Ct
value of allele 1 - Ct value of allele 2) value was calculated as an
average of triplicate reactions. In gDNA samples, delta Ct values
were calculated as an average of duplicate reactions. Only the
samples with #10% standard errors in dCt were used for further
analysis.
Allelic expression for each cDNA sample was normalized
against the overall average ratio obtained for gDNA from each
run. Subjects with greater than 2-fold difference in relative ASE
(cDNA allelic expression/gDNA allelic expression) possess allelic
expression imbalance (AEI). To verify our AEI determination
threshold was accurate, we applied the Davies-Bouldin (DB)
validity index [29]. The lowest values of the index reflect that
within a bin the measurements are more similar to each other than
the measurements in the other bins [29].

Association analysis of genetic effect on CHRNA5 and
PSMA4 total mRNA expression
To obtain a normal distribution, we log transformed relative
total mRNA expression. Association between SNP genotype and
relative total mRNA expression of CHRNA5 and PSMA4 was
performed in PLINK [27] using linear regression under an
additive genetic model. To minimize possible effects of sample
heterogeneity, we performed our association analysis in subjects of
each ancestral group separately. Similar to our observation in
European Americans, postmortem interval (PMI = 13.96
6.0 hour in samples of African ancestry; 22.5614.7 hour in
samples of European ancestry) had a weak effect on CHRNA5
mRNA expression levels in brains of African ancestry and this
variable was included as a covariate for association analysis. Age
and gender did not affect CHRNA5 expression and were not
included as covariates. For PSMA4 mRNA expression analysis, age
had a weak effect in brains of European ancestry but not in
samples of African ancestry; therefore this variable was included as
a covariate for association analysis in the European ancestry
datasets. PMI and gender did not influence PSMA4 mRNA
expression.

Results
Total CHRNA5 mRNA level in frontal cortex is strongly
associated with variants located upstream of the gene in
individuals of both African and European ancestry

Allele-specific expression (ASE)

Similar to our previous study in human brains of European
ancestry [19,20], the variability in CHRNA5 total mRNA
expression levels in frontal cortices of African ancestry is
significantly associated with rs880395 (p = 7.2761027),
rs3841324 (p = 6.9461023), and rs588765 (p = 1.1061024)
(Table 1). Subjects homozygous for the minor allele at rs880395
and rs3841324, and rs588765 showed 5.4-fold, 2.6-fold, and 4.7fold increase in CHRNA5 mRNA expression levels compared to
the major allele homozygotes, respectively (Figure 1).
The insertion-deletion variant rs3841324 within the putative
promoter region of CHRNA5 is highly correlated with rs880395
and rs588765 (r2.0.8; Figure S1a) in our brain samples of
European ancestry, however it is very weakly correlated with
rs880395 (r2 = 0.12) and rs588765 (r2 = 0.16) in brain samples of
African ancestry (Figure S1b). rs588765 has a modest correlation
with rs880395 in samples of African ancestry (r2 = 0.63; Figure
S1b). To test whether the associations of CHRNA5 mRNA
expression with rs3841324 and with rs588765 are due to the LD
with rs880395, we performed conditional analyses. When the
effect of rs880395 on CHRNA5 mRNA expression was included as
a covariate, the association between rs3841324 or rs588765 and
CHRNA5 expression level was no longer significant in samples of
African ancestry or in samples of European ancestry. Conversely,
in conditional analysis controlling for the effect of rs3841324, the
association of rs880395 with CHRNA5 mRNA expression remains
statistically significant in samples of African ancestry
(p = 1.7961025) and in samples of European ancestry
(p = 1.9961023). Similarly, conditional analysis showed rs880395
remains significantly associated with CHRNA5 expression in both
samples of African ancestry (p = 1.8661025) and European
ancestry (1.3861025) after controlling for the effect of rs588765.
To further investigate eQTLs within and flanking the CHRNA5
gene, we genotyped twenty additional SNPs including 2 variants
(rs601079, rs615470) that are associated with CHRNA5 total
mRNA expression levels in brain tissues of European ancestry
reported in our previous study [20], 5 tag SNPs (rs55853698,
rs16969968, rs578776, rs3743078, rs6495308) from different LD
bins in the CHRNA5-A3-B4 gene cluster [19], and 12 SNPs highly
correlated with rs880395 in the European population (r2 = 0.9).
The linear regression results with postmortem interval as a
covariate showed that the most significant variants associated with

Allelic mRNA expression level is determined by comparing the
number of genomic DNA molecules for each allele with the
number of allelic mRNA molecules within the same individual and
same tissue, thus mRNA expression levels from the paternal and
maternal alleles would be the same unless there are cis-regulatory
variants that affect gene expression. We selected subjects with
heterozygous genotypes for the coding SNP (rs16969968) and/or a
SNP (rs615470) in the 39UTR of CHRNA5 for allele-specific
expression measures. TaqMan genotyping assays for rs16969968
(Life technologies, C_26000428_20) and rs615470 (Life technologies, C_18757_10) are within the CHRNA5 transcript, and were
used for allele specific quantitative RT-PCR in each genomic
DNA and cDNA. To enhance RT-PCR template, we preamplified gDNA and cDNA using primers flanking the region
targeted by the TaqMan genotyping assay and ran a standard
PCR reaction for 20 cycles. Primers used for rs16969968 preamplification are: forward primer 59-CGCCTTTGGTCCGCAAGATA-39 and reverse primer 59-TGCTGATGGGGGAAGGTGGAG-39. Primers used for rs615470 pre-amplification
are: forward primer 59- CAGATGATCCATTTGAACAGTTGGC-39 and reverse primer 59- TAGAGACGGGGTTTCTCCACGTTG-39. Portions of pre-amplified cDNA from heterozygous samples for rs16969968 and/or rs615470 were arrayed in
triplicate onto 384-well plates. As a control, a portion of preamplified gDNA from matched samples was also arrayed in
duplicate onto the same 384-well plate. All reactions were
evaluated on an ABI-7900HT Fast real-time PCR system under
standard conditions.

Determination of allelic mRNA expression imbalance
(AEI)
The transcript level in each sample should be identical for allele
1 and allele 2 unless there is a cis-regulatory effect of one allele that
changes its relative expression level. Therefore, one allele serves as
the control for the other. To evaluate the amplification efficiency
for allelic mRNA expression, we first set up a dilution series using
one sample (cDNA or gDNA) that was homozygous for allele 1
and another sample that was homozygous for allele 2. The RTPCR efficiency for each allele ranges from 95% to 100% with the
cDNA sample. In the gDNA sample, the amplification efficiency
PLOS ONE | www.plosone.org
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AEI-negative individuals (Figure 4a). Ten subjects were AEIpositive with 2.2 - 7.5-fold difference in relative ASE; 5 subjects
were AEI-negative (Figure 4b). Our ANOVA analysis showed the
difference of relative ASE between AEI-positive and AEI-negative
subsets is statistically significant at p = 1.6261023. The correlation
between two experiments of ASE assays is 0.97.

altered mRNA expression levels are located upstream of the
CHRNA5 transcript (Table 1).

Tissue-specific effect on the variability of CHRNA5 mRNA
levels
We tested whether eQTLs for CHRNA5 expression found in
human brain are also present in lymphoblastoid cells. We
measured CHRNA5 total mRNA expression levels in 60 lymphoblastoid cell lines from European Americans and 60 lymphoblastoid cell lines from African Americans and examined the effect of
rs880395 and rs3841324 on expression. In cells from European
Americans, both rs880395 (p = 1.0261023) and rs3841324
(p = 6.061024) were significantly associated with variability of
CHRNA5 mRNA expression. However, the effect is much weaker
and is in the opposite direction to the effect detected in frontal
cortex. The minor alleles of rs880395 and rs3841324 are
associated with increased mRNA expression of CHRNA5 in
human frontal cortex (Figure 1) but they are associated with
decreased mRNA expression of CHRNA5 in lymphoblastoid cells
(Figure S2a). In cells from African Americans, no significant effect
of rs880395 or rs3841324 on CHRNA5 mRNA expression was
observed (Figure S2b).

Potential functional variants that affect CHRNA5 mRNA
expression
In this study we detected reproducible allelic expression of
CHRNA5 mRNA in frontal cortex of African Americans,
Australians and European Americans. Therefore, we used allelic
mRNA expression imbalance as a phenotypic trait to identify
functional cis-acting variants. In frontal cortices of European
ancestry, subjects who were AEI-positive (ASE .2) detected by
either rs16969968 or rs615470 are heterozygous for 13 of the 23
variants genotyped (Figures 2b and 3b). These 13 variants, flanked
by rs12916483 and rs4275821, are in a .12 kb region spanning
from upstream of the CHRNA5 transcription site (28,521 bp
relative to the AUG of CHRNA5) to upstream of the PSMA4
transcription start site (2358 bp relative to the AUG of PSMA4)
(Table 1, Figure 5). Subjects who were AEI-negative (ASE ,2) are
homozygous for all 13 variants. The concordance of AEI-positive
with heterozygosity suggests that the difference in mRNA
expression is affected by variants in this region.
We then tested the cis-acting effect in frontal cortex from
individuals of African ancestry. All 10 subjects who were AEIpositive are heterozygous for 10 variants in a ,9 kb region
(222.3 kb to 213.2 kb relative to the AUG of CHRNA5), defined
by an intronic SNP (rs11858230) of PSMA4 and rs7164030 located
upstream of CHRNA5 (Figures 4b and 5). Five subjects who were
AEI-negative are homozygous for these 10 variants. This analysis
suggests that the potential functional variants altering CHRNA5
mRNA expression levels are likely located in this region.

Allelic expression imbalance (AEI) analysis in frontal
cortices from European Americans/Australians
To further confirm the cis-regulatory effect on CHRNA5
transcript levels and identify potential variants responsible for
modulating mRNA expression, we performed allele specific
expression (ASE) assays. We identified 49/111 and 55/111 brain
samples derived from European Americans/Australians that are
heterozygous for rs16969968 and rs615470, respectively.
We first applied the Davies-Bouldin (DB) validity index [29] to
verify that relative ASE = 2 is an appropriate threshold for AEI
analysis. Our analysis showed the lowest DB index was at the
threshold between ASE = 1.78 and ASE = 3.48 for rs16969968
(Figure 2a). The lowest DB index for rs615470 was at the
threshold between ASE = 1.29 and ASE = 2.23 (Figure 3a). After
excluding samples that failed in ASE assays and those with ,90%
genotyping success rate, 30 subjects showed more than 2-fold
difference in relative ASE (AEI-positive) quantified with
rs16969968; 14 subjects had ASE ,2 and were determined to
be AEI-negative (Figure 2b). Using ANOVA analysis, we detected
strongly significant difference in relative ASE between AEIpositive and AEI-negative subsets (p-value = 1.85610218). With
assay of rs615470, there were 39 AEI-positive subjects with 2.27.1-fold difference in relative ASE which is significantly different
(p-value = 1.9461029) from the relative ASE in the AEI-negative
subset (6 subjects) (Figure 3b).
The correlation of relative ASE measures between two
experimental runs was 0.91 and 0.76 for rs16969968 and
rs615470, respectively. We also compared the allelic mRNA
expression in 26 samples that are heterozygous for both
rs16969968 and rs615470 and observed consistent relative allelic
expression (correlation = 0.74) between the two markers (Figure
S3).

Association of SNP rs880395 and highly correlated
variants with PSMA4 mRNA level in human frontal
cortices
Because 4 of the 10 potentially functional variants associated
with CHRNA5 mRNA expression are within the PSMA4 region, we
tested whether these variants are also associated with PSMA4
mRNA levels. We observed variability of PSMA4 mRNA levels in
both samples of African ancestry and European ancestry.
However, the PSMA4 mRNA expression observed in frontal
cortices is not correlated with the level of CHRNA5 mRNA
expression (correlation = 20.13, p = 0.2 in samples of European
ancestry; correlation = 0.03, p = 0.8 in samples of African
ancestry). Using linear regression with age as a covariate, none
of the 23 variants tested is associated with PSMA4 mRNA levels in
frontal cortices of European ancestry (Table S2). In brains of
African ancestry, 4 of 22 polymorphic variants tested showed
marginal
association
with
PSMA4
mRNA
levels
(5.9661023#p#3.9161022), but the association is no longer
significant after correcting for multiple testing (q value $0.13).

Discussion

Allelic expression imbalance analysis in frontal cortices
from African Americans

The cis-regulatory effect on CHRNA5 mRNA expression in
frontal cortex from individuals of African ancestry is the same as
observed in frontal cortex from individuals of European ancestry.
In populations of European ancestry variants that alter CHRNA5
mRNA expression levels are in an extensive linkage disequilibrium
bin spanning ,200 kb, with correlation coefficient (r2) of 0.7. In
populations of African ancestry they fell into 7 bins (r2$0.7) (Table

Because rs16969968 is rare in African Americans (minor allele
frequency ,0.05), we only used rs615470 to measure ASE.
Applying the DB validity index, we detected the lowest DB index
at the threshold between ASE = 1.52 and ASE = 2.53, which
confirmed our threshold of relative ASE = 2 for AEI-positive and
PLOS ONE | www.plosone.org
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8.18

8.77

8.01

8.06

1.73E-04

1.16E-04

4.40E-02

3.40E-05

9.83E-03

2.89E-10

3.11E-10

1.22E-03

4.48E-13

1.46E-07

3.21E-12

1.60E-12

1.60E-12

5.57E-13

1.60E-12

1.60E-12

1.60E-12

3.87E-12

1.60E-12

1.31E-13

3.88E-12

3.04E-12

9.92E-13

P

47

47

47

47

47

47

47

47

47

47

46

47

47

44

47

45

47

47

47

45

46

47

47

5.77

5.54

5.77

5.77

5.14

4.99

5

4.72

2.51

STAT

20.35

0.36

0.38

0.43

20.11

0.46

0.54

20.12

0.39

0.61

0.68

0.67

0.67

22.54

2.62

2.78

3.13

20.75

3.51

4.25

20.8

2.83

5.21

5.78

5.77

5.77

not polymorphic

0.67

0.66

0.67

0.67

0.63

0.63

0.63

0.6

0.36

BETA

1.45E-02

1.21E-02

7.99E-03

3.07E-03

4.57E-01

1.04E-03

1.10E-04

4.29E-01

6.94E-03

4.84E-06

7.65E-07

7.27E-07

7.27E-07

7.27E-07

1.85E-06

7.27E-07

7.27E-07

6.10E-06

1.12E-05

1.02E-05

2.40E-05

1.58E-02

P

N

STAT

N

BETA

Frontal cortex of African ancestry (PMI as a
covariate)

Frontal cortex of European ancestry (PMI as a
covariate)

*Bolded beta values indicate variants with significant association between minor alleles and increased mRNA expression.
doi:10.1371/journal.pone.0080204.t001

78888400

rs578776

78885988

78842239

rs1979907

rs615470

intronic region of CHRNA5

78841220

78869579

78837801

rs4887062

rs8053

78882925

78836362

rs8025429

rs601079

78835552

rs11858230

rs16969968

intronic region of CHRNA5

78833758

rs4886571

2358 bp relative to AUG of PSMA4

78832397

rs12916483

Gene

chr 15 position
(build 37)

SNP

Table 1. Association of CHRNA5 total mRNA expression with variants within and flanking the CHRNA5 gene.
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Figure 1. Minor allele of rs880395 (A allele), rs3841324 (S allele) and rs588765 (T allele) are associated with increased total mRNA
expression of CHRNA5 in human frontal cortex of African Americans.
doi:10.1371/journal.pone.0080204.g001

S1), allowing us to map the functional variants influencing
CHRNA5 mRNA expression to a ,9 kb region upstream of the
CHRNA5 transcription start site (222.3 kb to 213.2 kb at AUG of
CHRNA5).
Among 10 potential causal variants tested, 4 SNPs, including
one synonymous SNP (rs8053), are within the PSMA4 region.

PSMA4, which encodes proteasome subunit alpha type-4, was
reported as a strong candidate mediator of lung cancer cell growth
[30]. Liu et al. [30] reported PSMA4 mRNA levels were increased
in lung tumors compared with normal lung tissues. However, no
change in PSMA4 mRNA expression was detected in another
study of paired normal lung and lung adenocarcinoma tissue [21].

Figure 2. Allele specific expression (ASE) analysis with rs16969968 in 44 frontal cortices of European ancestry. 2a. Davies-Bouldin (DB)
validity index analysis. Columns represent the ASE. Dotted line represents the DB validity index. The red dot indicates the optimal cutoff predicted by
the DB index that coincides with ASE. 2b. Concordance of allelic expression variation with heterozygosity. Samples #1 to #14 which show relative
allelic expression balance (*ASE,2) are homozygous for the 13 highlighted SNPs. Samples #15 to #44 which show relative allelic expression
imbalance are heterozygous for all 13 SNPs. *See material and method for details; ASE: allele specific expression. { Indicates samples are also
heterozygous for rs615470.
doi:10.1371/journal.pone.0080204.g002
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Figure 3. Allele specific expression (ASE) analysis with rs615470 in 45 frontal cortices of European ancestry. 3a. Davies-Bouldin (DB)
validity index analysis. Columns represent the ASE. Dotted line represents the DB validity index. The red dot indicates the optimal cutoff predicted by
the DB index that coincides with ASE. 3b. Concordance of allelic expression variation with heterozygosity. Samples #1 to #6 which show relative
allelic expression balance (*ASE,2) are homozygous for the 13 highlighted SNPs. Samples #7 to #45 which showed relative allelic expression
imbalance are heterozygous for all 13 SNPs. *See material and method for details; ASE: allele specific expression. { Indicates samples are also
heterozygous for rs16969968.
doi:10.1371/journal.pone.0080204.g003

Figure 4. Allele specific expression (ASE) analysis with rs615470 in 15 frontal cortices of African ancestry. 4a. Davies-Bouldin (DB)
validity index analysis. Columns represent the ASE. Dotted line represents the DB validity index. The red dot indicates the optimal d cutoff predicted
by the DB index that coincides with ASE. 4b. Concordance of allelic expression variation with heterozygosity. Samples #1 to #5 which show relative
allelic expression balance (*ASE,2) are homozygous for all 10 SNPs highlighted. Samples #6 to #15 which show relative allelic expression imbalance
are heterozygous for all 10 SNPs. *See material and method for details; ASE: relative allele specific expression.
doi:10.1371/journal.pone.0080204.g004
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Figure 5. A schematic of CHRNA5 and PSMA4 gene structures. SNPs in red indicate potential functional eQTLs. Note: figure is not drawn to
scale.
doi:10.1371/journal.pone.0080204.g005

For example, significant eQTLs that mapped to the Parkinson
disease associated gene, MAPT were only detected in post-mortem
brains but not in blood [32]. In this study, we detected a consistent
cis-regulatory effect on the variability of CHRNA5 mRNA levels in
human frontal cortices of African and European ancestry but not
in lymphoblastoid cell lines, which supports the importance of
examining gene expression in brain, especially for psychiatric
traits. Future studies examining other brain regions involved in the
reward pathway may further define whether the eQTL for
CHRNA5 mRNA expression is limited to frontal cortex or is shared
across brain regions.
A further limitation of this study is the absence of a direct assay
of a5 protein in brain tissue. There are several caveats when
mRNA transcript level is used as a proxy for functional receptor
number. The mRNA level largely reflects the content of the
somato-dendritic compartment, while it is very likely that most
receptors incorporating the a5 subunit are located in the terminal
regions of the cell [35]. Further, it is known that the number of
receptors containing a subunit protein can change by up to 2-fold
in the absence of a change in mRNA content (for example, a study
by Pauly et al)[36]. Finally, the amount of a5 subunit protein
available has been shown to strongly influence the assembly of
receptors containing a4 and b2 subunits [37] and so the ultimate
level of functional receptors containing the a5 subunit may be
influenced by additional factors. Because of these factors it is not
possible to directly link our measured effects on transcription to a
predicted change in the availability of functional cell-surface
receptors containing the a5 subunit. However, a reduction in
transcript availability has the potential to have widespread effects
on the number and subunit stoichiometry of surface receptors.
In summary, our allele specific expression analysis in human
brains of African and European ancestry confirmed the cisregulatory effect on CHRNA5 mRNA expression and implicated
variants in a 2.5 kb region upstream of CHRNA5 transcription site
as the putatively functional variants.

Our eQTL analysis showed none of the variants tested within and
flanking CHRNA5 and PSMA4 is associated with PSMA4 total
mRNA levels (Table S2). In addition, we did not observe any
correlation between CHRNA5 and PSMA4 mRNA expression in
the brain samples tested. It is possible that the association between
the 4 SNPs in PSMA4 (rs11858230, rs8025429, rs4887062 and
rs8053) and the changes in CHRNA5 transcript levels results from
the LD between these SNPs with rs880395.
The strong concordance between CHRNA5 differential allele
expression and heterozygosity detected in this study suggests that
one or more of the 6 SNPs (rs1979907, rs1979906, rs1979905,
rs880395, rs905740, and rs7164030), in a single LD bin (with
r2$0.94, D9 = 1 in populations of both African and European
ancestry) spanning ,2.5 kb at the 59 distal region of the CHRNA5
transcript are potential causal variants that alter the mRNA
expression of this gene. This study reinforces previous findings that
these 6 variants account for allelic expression differences in overall
CHRNA5 mRNA expression in human frontal cortices [23] and
possibly in the human amygdala and nucleus accumbens [25].
Quantitative mRNA expression analysis in this study and
previous studies have demonstrated that minor alleles of variants
in the adjacent CHRNA5 promoter region and/or 59distal
promoter region increase CHRNA5 mRNA levels in post-mortem
brain tissues and in lung tissue [19–21]. However, Doyle et al
conducted a functional study that incorporated an 852 bp portion
of the 59 distal region of the CHRNA5 promoter and showed
strongly repressed transcription in cells with heterologous
promoter constructs, compared to control vector [25]. No
significant difference of the relative promoter activities was
detected between the all-minor-allele haplotype construct and
the all-major-allele haplotype construct [25]. The contradictory
findings between the in vitro study and ex vivo study maybe
explained by exclusion of the regions of the CHRNA5 gene and
adjacent promoter from the constructs used in Doyle et al study.
Another possibility could be the tissue-specific nature of CHRNA5
RNA expression. For example, we observed that the genetic effects
on CHRNA5 total mRNA expression in lymphoblastoid cells of
European ancestry are in the opposite direction to that observed in
human brains. Studies with promoter haplotypes, including
rs3841324 and/or rs503464 within the CHRNA5 promoter region
and rs55853698 and rs55781567 within the 59UTR, have shown
that CHRNA5 transcriptional activity was modulated by the
promoter haplotype [21,25]. It is possible that CHRNA5
transcription is affected by variants in the 59UTR, and adjacent
and the 59distal region of the CHRNA5 promoter.
eQTLs are common in the human genome; some eQTLs are
shared across tissues and some are tissue-specific [31–34]. A recent
study integrating GWAS SNPs and gene expression profiles in
blood and brain demonstrated that brain tissue is required for
eQTL discovery for neurological diseases and psychiatric traits.
PLOS ONE | www.plosone.org

Supporting Information
Figure S1 a. Linkage disequilibrium between variants in human

brains of European ancestry. Number in each square represents
the correlation (r2) between 2 variants genotyped in 111 frontal
cortices included in this study. b. Linkage disequilibrium between
variants in human brains of African ancestry. Number in each
square represents the correlation (r2) between 2 variants genotyped
in 49 frontal cortices included in this study.
(TIFF)
Figure S2 a. Minor allele of rs880395 (A allele) and rs3841324
(S allele) are associated with decreased relative CHRNA5 total
mRNA expression (CHRNA5 total mRNA expression/GAPDH
total mRNA expression) in lymphoblastoid cells of European
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The Collaborative Study on the Genetics of Alcoholism
(COGA)
COGA, Principal Investigators B. Porjesz, V. Hesselbrock, H. Edenberg, L. Bierut, includes ten different centers: University of Connecticut (V.
Hesselbrock); Indiana University (H.J. Edenberg, J. Nurnberger Jr., T.
Foroud); University of Iowa (S. Kuperman, J. Kramer); SUNY Downstate
(B. Porjesz); Washington University in St. Louis (L. Bierut, A. Goate, J.
Rice, K. Bucholz); University of California at San Diego (M. Schuckit);
Rutgers University (J. Tischfield); Southwest Foundation (L. Almasy),
Howard University (R. Taylor) and Virginia Commonwealth University
(D. Dick). A. Parsian and M. Reilly are the NIAAA Staff Collaborators. We
continue to be inspired by our memories of Henri Begleiter and Theodore
Reich, founding PI and Co-PI of COGA, and also owe a debt of gratitude
to other past organizers of COGA, including Ting-Kai Li, currently a
consultant with COGA, P. Michael Conneally, Raymond Crowe, and
Wendy Reich, for their critical contributions.
The Collaborative Study on the Genetics of Nicotine Dependence (COGEND)
In memory of Theodore Reich, founding Principal Investigator of
COGEND, we are indebted to his leadership in the establishment and
nurturing of COGEND and acknowledge with great admiration his
seminal scientific contributions to the field. Lead investigators directing
data collection are Laura Bierut, Naomi Breslau, Dorothy Hatsukami, and
Eric Johnson. The authors thank Heidi Kromrei and Tracey Richmond for
their assistance in data collection.
The COGEND project is a collaborative research group and part of the
National Institute on Drug Abuse (NIDA) Genetics Consortium.

Americans. Y-axis represents the log10 values of relative CHRNA5
total mRNA expression. b. Minor allele of rs880395 (A allele) and
rs3841324 (S allele) are not associated with relative CHRNA5 total
mRNA expression (CHRNA5 total mRNA expression/GAPDH
total mRNA expression) in lymphoblastoid cells of African
Americans. Y-axis represents the log10 values of relative CHRNA5
total mRNA expression.
(TIFF)
Figure S3 Correlation of relative allele specific expression
(cDNA ASE/gDNA ASE) between rs16969968 and rs615470 in
frontal cortex of European ancestry.
(TIFF)
Table S1 Linkage disequilibrium (represented by bin number)
among SNPs associated with CHRNA5 mRNA expression using
HapMap release 2_22 data.
(DOCX)
Table S2 Association of relative PSMA4 total mRNA expression
(PSMA4 total mRNA expression/GAPDH total mRNA expression)
with variants within and flanking CHRNA5 gene.
(DOCX)
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